About This Deal

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. acquired HemaCare Corporation for $379.8 million in cash, a transaction completed in January 2020, structured as all cash.

HemaCare Corporation operates in Manufacturing Support — Biologics / cell therapy, is based in United States (Los Angeles, California). HemaCare Corporation was a business specializing in the production of human-derived cellular products for the cell therapy market.

The acquisition of HemaCare expands our comprehensive portfolio of early-stage research and manufacturing support solutions to encompass the production and customization of high-quality, human-derived cellular products to better support clients' cell therapy programs. The purchase price of HemaCare was $379.8 million in cash.

Manufacturing Support segment, cell therapy

Deal Terms

Acquirer
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Target
HemaCare Corporation
Value
$379.8 million in cash
Date
January 2020
Type
Full acquisition
Status
Ready

Transaction Details

Target HQ
United States (Los Angeles, California)
Segment
Manufacturing Support — Biologics / cell therapy
Structure
All cash
Announced
January 3, 2020
Closed
January 3, 2020

In Their Words

The acquisition of HemaCare expands our comprehensive portfolio of early-stage research and manufacturing support solutions to encompass the production and customization of high-quality, human-derived cellular products to better support clients' cell therapy programs. The purchase price of HemaCare was $379.8 million in cash.Charles River FY2020 10-K, Business Acquisitions note

Advisors

Advisory firms were not disclosed for this transaction.

Related Deals & Entities

Sources: Press release ↗

See how Top Bucket AI works for your firm

Request Demo
Top Bucket AI Research

Stay ahead of private markets

Research and market intelligence for private-markets professionals.

✓

You're subscribed.

Thanks for signing up.